SOUTH SAN FRANCISCO, CA -- (MARKET WIRE) -- May 24, 2007 -- Theravance, Inc. (NASDAQ: THRX) announced today that results from a series of in vitro and in vivo studies as well as Phase 1 human clinical studies with an investigational gastrointestinal (GI) motility compound, TD-5108, were presented at the 2007 Digestive Disease Week (DDW) in Washington, D.C. DDW is a large scientific meeting where clinical and preclinical scientists and practicing physicians from all over the world meet to share results of investigations and learn about the newest advances in mechanisms and treatment of gastrointestinal diseases.
